Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma
TTFields has been approved by the FDA for the treatment of patients with glioblastoma multiforme. However, the clinical effect and safety of radiotherapy concurrent of TTFields is not definite. In this study, the investigators conduct a phase II clinical trial to evaluate the efficacy and safety of this strategy.
Glioma|Glioblastoma
DEVICE: TTFields
Disease-free survival, the length of time after primary treatment for glioblastoma ends that the patient survives without any signs or symptoms of glioblastoma., 1 year
Overall survival, The length of time from the date of diagnosis to death from cancer, 2 years
the investigators plan to recruit 30 patients to evaluate the efficacy and safety of this strategy.